CIK 0001785279
- Emerging growth company
Metagenomi Therapeutics, Inc.
Sign in to watch- Ticker
- MGX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 813909017
- Phone
- +1 510-871-4880
- Business address
- 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
- Former names
- Metagenomi, Inc., Metagenomi Technologies, LLC
- 4 Open-market sale Wein Matthew sold 930 shares at $1.87 ($1,744)
- 4 Open-market sale Chief Financial Officer sold 1,808 shares at $1.87 ($3,390)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Financial Officer sold 1,559 shares at $1.86 ($2,900)
- 4 Open-market sale Chief Financial Officer sold 6,265 shares at $2.88 ($18,043)
- 4 Grant or award Irish Jian acquired 70,471 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Scientific Officer acquired 69,316 shares (grant or award)
- 4 Grant or award Wein Matthew acquired 10,397 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 69,316 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 57,763 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Harnest Simon acquired 11,552 shares (grant or award)
- 4 Grant or award Delaney Simren acquired 6,931 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Executive Officer acquired 118,992 shares (grant or award)
- 4 Open-market buy 10% owner bought 900,000 shares at an average $14.47 ($13,025,000)
- 4 Conversion 10% owner acquired 4,050,997 shares (conversion)
- 3 Insider Initial Statement of Ownership
Page 3 of 4 · 73 filings